收费全文 | 43967篇 |
免费 | 1947篇 |
国内免费 | 378篇 |
耳鼻咽喉 | 444篇 |
儿科学 | 954篇 |
妇产科学 | 488篇 |
基础医学 | 5824篇 |
口腔科学 | 728篇 |
临床医学 | 2619篇 |
内科学 | 11317篇 |
皮肤病学 | 1020篇 |
神经病学 | 3321篇 |
特种医学 | 1781篇 |
外科学 | 7673篇 |
综合类 | 176篇 |
一般理论 | 6篇 |
预防医学 | 1132篇 |
眼科学 | 1001篇 |
药学 | 2717篇 |
中国医学 | 170篇 |
肿瘤学 | 4921篇 |
2023年 | 243篇 |
2022年 | 498篇 |
2021年 | 886篇 |
2020年 | 468篇 |
2019年 | 653篇 |
2018年 | 912篇 |
2017年 | 691篇 |
2016年 | 883篇 |
2015年 | 966篇 |
2014年 | 1243篇 |
2013年 | 1587篇 |
2012年 | 2556篇 |
2011年 | 2853篇 |
2010年 | 1619篇 |
2009年 | 1484篇 |
2008年 | 2685篇 |
2007年 | 2904篇 |
2006年 | 2934篇 |
2005年 | 2941篇 |
2004年 | 3055篇 |
2003年 | 3098篇 |
2002年 | 3063篇 |
2001年 | 463篇 |
2000年 | 382篇 |
1999年 | 535篇 |
1998年 | 761篇 |
1997年 | 642篇 |
1996年 | 600篇 |
1995年 | 504篇 |
1994年 | 455篇 |
1993年 | 489篇 |
1992年 | 305篇 |
1991年 | 302篇 |
1990年 | 242篇 |
1989年 | 229篇 |
1988年 | 232篇 |
1987年 | 179篇 |
1986年 | 148篇 |
1985年 | 157篇 |
1984年 | 162篇 |
1983年 | 122篇 |
1982年 | 124篇 |
1981年 | 158篇 |
1980年 | 131篇 |
1979年 | 84篇 |
1978年 | 102篇 |
1977年 | 79篇 |
1976年 | 64篇 |
1975年 | 54篇 |
1974年 | 40篇 |
Purpose
This randomized, controlled trial evaluated the clinical efficacy of Billroth I (BI) and Roux-en-Y (RY) reconstruction at 1 year after distal gastrectomy for gastric cancer.Methods
The primary end point was the amount of body weight lost at 1 postoperative year, and secondary end points included other items related to nutritional status such as serum albumin and lymphocyte count, as well as endoscopic examination findings of the remnant stomach and esophagus. Of the 332 patients enrolled, 163 were assigned to the BI group and 169 were randomized to the RY group.Results
The loss in body weight 1 year after surgery did not differ significantly between the BI and RY groups (9.1 % and 9.7 %, respectively, p = 0.39). There were no significant differences in other aspects of nutritional status between the 2 groups. Endoscopic examination 1 year after gastrectomy showed reflux esophagitis in 26 patients (17 %) in the BI group versus 10 patients (6 %) in the RY group (p = 0.0037), while remnant gastritis was observed in 71 patients (46 %) in the BI group versus 44 patients (28 %) in the RY group (p = 0.0013); differences were significant for both conditions. Multivariable analysis showed that the only reconstruction was the independently associated factor with the incidence of reflux esophagitis.Conclusions
RY reconstruction was not superior to BI in terms of body weight change or other aspects of nutritional status at 1 year after surgery, although RY more effectively prevented reflux esophagitis and remnant gastritis after distal gastrectomy. 相似文献Background
Downstream activation through receptor tyrosine kinases (RTKs) plays important roles in carcinogenesis. In this study, we assessed the clinical involvement of Axl, an RTK, and its ligand, Gas6, in surgically treated lung adenocarcinoma.Methods
Axl and Gas6 mRNA and protein expression levels were quantified using quantitative real-time polymerase chain reaction and immunohistochemistry, respectively, in completely resected lung adenocarcinoma tissues (n = 88) and were evaluated for correlation with clinicopathologic features and patient survival.Results
Higher expressions of Axl mRNA/protein and Gas6 protein were significantly related to worse clinicopathological features and prognosis (5-year overall survival rates: Axl mRNA low: 72.3 %, high: 49.7 %, P = 0.047; Axl protein low: 77.5 %, high: 38.6 %, P < 0.001; and Gas6 protein low: 70.5 %, high: 48 %, P = 0.042). On the contrary, higher Gas6 mRNA expression was related to better clinicopathological features and prognosis (5-year overall survival rates: Gas6 mRNA low: 59.2 %, high: 81.8 %, P = 0.054). Multivariate analysis suggests that high Axl mRNA expression may be an independent factor for poor patient prognosis (P = 0.04).Conclusions
In lung adenocarcinoma, Axl and Gas6 expression levels were associated with tumor advancement and patient survival, thus rendering them as reliable biomarkers and potential targets for treatment of lung adenocarcinoma.The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor. We previously reported the beneficial effects of interferon alpha (IFN) and 5-fluorouracil (5-FU) combination therapy for these patients. We showed that the mechanism of therapy was regulation of vascular endothelial growth factor (VEGF). Here, we combined IFN/5-FU therapy with the VEGF receptor–selective inhibitor PTK787/ZK222584 (PTK/ZK) and examined the antitumor effects and the mechanism of action.
MethodsWe studied two HCC cell lines, PLC/PRF/5 and HuH7, and a human umbilical vein endothelial cell line, HUVEC. We studied the effects of IFN/5-FU with or without PTK/ZK in growth inhibition assays, immunohistochemistry, Western blot analysis, and immunocytochemistry.
ResultsIn a HuH7 xenograft model, the combination of PTK/ZK and IFN/5-FU significantly inhibited proliferation, induced apoptosis, decreased microvessel density, reduced the number of tumor cells that expressed VEGF receptor 2 (VEGFR-2), and repressed the phosphorylation of Akt in vivo. In HCC cells and HUVECs in vitro, IFN/5-FU plus PTK/ZK repressed the expression of VEGFR-2 and repressed the phosphorylation of VEGFR, Akt, Erk, and p38MAPK.
ConclusionsVEGF signaling inhibition enhanced the antitumor effects of IFN/5-FU therapy on HCC cells and endothelial cells via Erk, Akt, and p38MAPK pathways.
相似文献